Drug Costs

Publication Title: 
Forschende Komplementarmedizin (2006)

Though homeopathy has been in successful and continuous use for well over 200 years, in the United Kingdom it is under growing pressure, from scientific detractors and sections of the media. As such, homeopathy's free National Health Service provision is threatened because it is derided as 'unproven', 'unscientific', and even 'deadly'. While refuting these and other detractions, this paper considers possible reasons for the current plight of homeopathy UK.

Author(s): 
Milgrom, Lionel R.
Publication Title: 
Health Affairs (Project Hope)

Research has demonstrated that Medicare beneficiaries with drug coverage consume more clinically essential drugs. However, generosity of coverage varies considerably across beneficiaries. This study examines the association between types of drug coverage and the consumption and cost per tablet of essential antihypertensive medications among beneficiaries with hypertension.

Author(s): 
Adams, A. S.
Soumerai, S. B.
Ross-Degnan, D.
Publication Title: 
Medical care research and review: MCRR

There is substantial variation in the generosity of public assistance programs that affect HIV+ patients, and these differences should affect the economic outcomes associated with HIV infection. This article uses data from a nationally representative sample of HIV+ patients to assess how differences across states in Medicaid and AIDS Drug Assistance Programs (ADAP) affect costs and labor market outcomes for HIV+ patients in care in that state.

Author(s): 
Goldman, D. P.
Bhattacharya, J.
Leibowitz, A. A.
Joyce, G. F.
Shapiro, M. F.
Bozzette, S. A.
Publication Title: 
Journal of Clinical Hypertension (Greenwich, Conn.)

This study employed a new-user design to assess predictors of persistence with antihypertensive therapy, with emphasis on prescription drug cost-sharing. This retrospective longitudinal analysis used 2001-2002 claims data from 45 large health plans. The sample consisted of 23,047 individuals with hypertension, aged 41 to 65 years and receiving new antihypertensive treatment of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, calcium channel blockers, or diuretics.

Author(s): 
Briesacher, Becky A.
Limcangco, M. Rhona
Frech-Tamas, Feride
Publication Title: 
Health Services Research

OBJECTIVES: To examine the impact of benefit generosity and household health care financial burden on the demand for specialty drugs in the treatment of rheumatoid arthritis (RA). DATA SOURCES/STUDY SETTING: Enrollment, claims, and benefit design information for 35 large private employers during 2000-2005. STUDY DESIGN: We estimated multivariate models of the effects of benefit generosity and household financial burden on initiation and continuation of biologic therapies.

Author(s): 
Karaca-Mandic, Pinar
Joyce, Geoffrey F.
Goldman, Dana P.
Laouri, Marianne
Publication Title: 
The American Journal of Managed Care

OBJECTIVES: To quantify how access to on-patent drugs by tier placement varies by insurance type and therapeutic area. STUDY DESIGN: Retrospective analysis of insurance plan drug coverage data. METHODS: Drug coverage information was collected from the Fingertip Formulary database in May 2011 for 3 drug classes (statins, angiotensin II receptor blockers, and protein-tyrosine kinase inhibitors) across 3 therapeutic areas with varying levels of generic drug availability.

Author(s): 
RÈgnier, Stephane A.
Publication Title: 
International Journal for Equity in Health

BACKGROUND: There is an urgent need for universal access to modern contraceptives in Nigeria, to facilitate the achievement of the Millennium Development Goals and other national goals. This study provides information on the potential role of community solidarity in increasing access to contraceptives for the most-poor people through exploration of the role of altruism by determining level of altruistic willingness to pay (WTP) for modern contraceptives across different geographic contexts in Nigeria.

Author(s): 
Onwujekwe, Obinna E.
Ogbonna, Chinwe
Uguru, Nkoli
Uzochukwu, Benjamin S. C.
Lawson, Agathe
Ndyanabangi, Bannet
Publication Title: 
British Journal of Clinical Pharmacology

Unlike human immunodeficiency virus (HIV) disease or tuberculosis, both of which are also major threats to public health throughout the tropics, uncomplicated falciparum malaria is relatively cheaply and rapidly cured, usually in Outpatients. However, in common with both HIV and TB (but to varying degrees), control of malaria is threatened by inadequate resources and drug resistance. Worldwide, it is Africa that carries the greatest burden of falciparum malaria mortality and morbidity; by no coincidence, it is also Africa that is most resource-limited.

Author(s): 
Winstanley, Peter
Publication Title: 
Bulletin of the World Health Organization

The serious threat posed by the spread of drug-resistant malaria in Africa has been widely acknowledged. Chloroquine resistance is now almost universal, and resistance to the successor drug, sulfadoxine-pyrimethamine (SP), is growing rapidly. Combination therapy has been suggested as being an available and potentially lasting solution to this impending crisis. However, the current cost of combination therapy, and especially that of artemisinin combination therapy (ACT), is potentially a serious drawback, even if a significant part of its cost is passed on to the end-user.

Author(s): 
Whitty, Christopher J. M.
Allan, Richard
Wiseman, Virginia
Ochola, Sam
Nakyanzi-Mugisha, Maria Veronicah
Vonhm, Benjamin
Mwita, Mahemba
Miaka, Constantin
Oloo, Aggrey
Premji, Zul
Burgess, Craig
Mutabingwa, Theonest K.
Publication Title: 
Tropical medicine & international health: TM & IH

INTRODUCTION: There is growing international evidence that artemisinin-based combination therapy (ACT) is one of the few effective measures available to 'Roll Back Malaria'. However, concerns about the costs and affordability of ACT are obstacles to its widespread implementation. This paper explores some economic aspects of the implementation of artemether-lumefantrine (AL) to replace sulphadoxine-pyrimethamine (SP) in the KwaZulu Natal (KZN) province, South Africa.

Author(s): 
Muheki, Charlotte
McIntyre, Di
Barnes, Karen I.

Pages

Subscribe to RSS - Drug Costs